OPNT Annual EBITDA
$5.82 M
+$7.37 M+476.30%
31 December 2021
Summary:
As of February 5, 2025, OPNT annual earnings before interest, taxes, depreciation & amortization is $5.82 million, with the most recent change of +$7.37 million (+476.30%) on December 31, 2021. During the last 3 years, it has risen by +$27.01 million (+127.49%).OPNT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
OPNT Quarterly EBITDA
-$9.51 M
+$1.79 M+15.84%
30 September 2022
Summary:
As of February 5, 2025, OPNT quarterly earnings before interest, taxes, depreciation & amortization is -$9.51 million, with the most recent change of +$1.79 million (+15.84%) on September 30, 2022. Over the past year, it has dropped by -$13.49 million (-338.81%).OPNT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
OPNT TTM EBITDA
-$30.70 M
-$13.49 M-78.35%
30 September 2022
Summary:
As of February 5, 2025, OPNT TTM earnings before interest, taxes, depreciation & amortization is -$30.70 million, with the most recent change of -$13.49 million (-78.35%) on September 30, 2022. Over the past year, it has dropped by -$34.16 million (-987.52%).OPNT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
OPNT EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +476.3% | -338.8% | -987.5% |
| 3 y3 years | +127.5% | -189.5% | -363.4% |
| 5 y5 years | +277.1% | -69.6% | -363.4% |
OPNT EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | -50.0% | -189.3% | -358.6% |
Opiant Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2022 | - | -$9.51 M(-15.8%) | -$30.70 M(+78.4%) |
| June 2022 | - | -$11.29 M(-3.9%) | -$17.21 M(+370.3%) |
| Mar 2022 | - | -$11.76 M(-731.5%) | -$3.66 M(-162.8%) |
| Dec 2021 | $5.82 M(-476.3%) | $1.86 M(-53.2%) | $5.82 M(+68.4%) |
| Sept 2021 | - | $3.98 M(+76.3%) | $3.46 M(+1371.2%) |
| June 2021 | - | $2.26 M(-199.2%) | $235.10 K(-110.6%) |
| Mar 2021 | - | -$2.28 M(+352.6%) | -$2.22 M(+43.1%) |
| Dec 2020 | -$1.55 M(-113.3%) | -$502.80 K(-166.5%) | -$1.55 M(-485.2%) |
| Sept 2020 | - | $756.60 K(-492.0%) | $401.80 K(-96.1%) |
| June 2020 | - | -$193.00 K(-88.0%) | $10.27 M(-13.5%) |
| Mar 2020 | - | -$1.61 M(-211.2%) | $11.87 M(+1.9%) |
| Dec 2019 | $11.65 M(-155.0%) | $1.45 M(-86.4%) | $11.65 M(+1884.9%) |
| Sept 2019 | - | $10.62 M(+651.2%) | $587.10 K(-105.4%) |
| June 2019 | - | $1.41 M(-177.4%) | -$10.97 M(-20.0%) |
| Mar 2019 | - | -$1.83 M(-81.0%) | -$13.71 M(-35.3%) |
| Dec 2018 | -$21.19 M(-1472.1%) | -$9.62 M(+923.4%) | -$21.19 M(+83.2%) |
| Sept 2018 | - | -$940.00 K(-28.9%) | -$11.57 M(-28.7%) |
| June 2018 | - | -$1.32 M(-85.8%) | -$16.23 M(+10.4%) |
| Mar 2018 | - | -$9.31 M(+66.0%) | -$14.71 M(-810.3%) |
| Dec 2017 | $1.54 M(-78.2%) | - | - |
| Oct 2017 | - | -$5.61 M(-2892.7%) | $2.07 M(-70.8%) |
| July 2017 | $7.10 M(-191.8%) | $200.70 K(-106.3%) | $7.10 M(+21.4%) |
| Apr 2017 | - | -$3.16 M(-129.7%) | $5.85 M(-38.0%) |
| Jan 2017 | - | $10.64 M(-1940.7%) | $9.42 M(+238.2%) |
| Oct 2016 | - | -$578.00 K(-44.9%) | $2.79 M(-136.0%) |
| July 2016 | -$7.74 M(+10.4%) | -$1.05 M(-354.5%) | -$7.74 M(-7.1%) |
| Apr 2016 | - | $412.40 K(-89.7%) | -$8.32 M(-21.3%) |
| Jan 2016 | - | $4.00 M(-136.0%) | -$10.58 M(-39.0%) |
| Oct 2015 | - | -$11.10 M(+577.5%) | -$17.33 M(+147.6%) |
| July 2015 | -$7.01 M(-38.1%) | -$1.64 M(-11.0%) | -$7.00 M(-26.4%) |
| Apr 2015 | - | -$1.84 M(-33.2%) | -$9.51 M(+15.7%) |
| Jan 2015 | - | -$2.76 M(+259.4%) | -$8.21 M(-21.8%) |
| Oct 2014 | - | -$766.80 K(-81.5%) | -$10.51 M(-7.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| July 2014 | -$11.32 M(+31.3%) | -$4.14 M(+658.1%) | -$11.33 M(+35.5%) |
| Apr 2014 | - | -$546.70 K(-89.2%) | -$8.36 M(-0.4%) |
| Jan 2014 | - | -$5.05 M(+217.9%) | -$8.39 M(-11.9%) |
| Oct 2013 | - | -$1.59 M(+34.8%) | -$9.53 M(+10.1%) |
| July 2013 | -$8.62 M(-30.2%) | -$1.18 M(+103.3%) | -$8.65 M(-4.7%) |
| Apr 2013 | - | -$579.30 K(-90.6%) | -$9.08 M(-8.9%) |
| Jan 2013 | - | -$6.18 M(+768.5%) | -$9.97 M(+19.2%) |
| Oct 2012 | - | -$711.60 K(-55.8%) | -$8.36 M(-32.3%) |
| July 2012 | -$12.36 M(+31.0%) | -$1.61 M(+9.5%) | -$12.36 M(-8.5%) |
| Apr 2012 | - | -$1.47 M(-67.9%) | -$13.51 M(-22.5%) |
| Jan 2012 | - | -$4.57 M(-2.8%) | -$17.44 M(+25.8%) |
| Oct 2011 | - | -$4.71 M(+70.5%) | -$13.86 M(+46.9%) |
| July 2011 | -$9.43 M(+367.9%) | -$2.76 M(-48.9%) | -$9.43 M(+31.8%) |
| Apr 2011 | - | -$5.40 M(+442.9%) | -$7.16 M(+262.1%) |
| Jan 2011 | - | -$994.40 K(+253.3%) | -$1.98 M(-11.0%) |
| Oct 2010 | - | -$281.50 K(-41.9%) | -$2.22 M(+10.2%) |
| July 2010 | -$2.02 M(>+9900.0%) | -$484.10 K(+123.0%) | -$2.02 M(+31.5%) |
| Apr 2010 | - | -$217.10 K(-82.5%) | -$1.53 M(+16.1%) |
| Jan 2010 | - | -$1.24 M(+1525.7%) | -$1.32 M(+1445.0%) |
| Oct 2009 | - | -$76.20 K(+4382.4%) | -$85.50 K(+481.6%) |
| July 2009 | -$14.70 K(-17.9%) | -$1700.00(-60.5%) | -$14.70 K(-41.2%) |
| Apr 2009 | - | -$4300.00(+30.3%) | -$25.00 K(+10.6%) |
| Jan 2009 | - | -$3300.00(-38.9%) | -$22.60 K(0.0%) |
| Oct 2008 | - | -$5400.00(-55.0%) | -$22.60 K(+26.3%) |
| July 2008 | -$17.90 K(-46.7%) | -$12.00 K(+531.6%) | -$17.90 K(-0.6%) |
| Apr 2008 | - | -$1900.00(-42.4%) | -$18.00 K(-15.1%) |
| Jan 2008 | - | -$3300.00(+371.4%) | -$21.20 K(+14.6%) |
| Oct 2007 | - | -$700.00(-94.2%) | -$18.50 K(-29.4%) |
| July 2007 | -$33.60 K | -$12.10 K(+137.3%) | -$26.20 K(+85.8%) |
| Apr 2007 | - | -$5100.00(+750.0%) | -$14.10 K(+48.4%) |
| Jan 2007 | - | -$600.00(-92.9%) | -$9500.00(+6.7%) |
| Oct 2006 | - | -$8400.00(+1580.0%) | -$8900.00(+1680.0%) |
| Apr 2006 | - | -$500.00(<-9900.0%) | -$500.00(<-9900.0%) |
| Jan 2006 | - | $0.00 | $0.00 |
FAQ
- What is Opiant Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Opiant Pharmaceuticals?
- What is Opiant Pharmaceuticals annual EBITDA year-on-year change?
- What is Opiant Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Opiant Pharmaceuticals?
- What is Opiant Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Opiant Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Opiant Pharmaceuticals?
- What is Opiant Pharmaceuticals TTM EBITDA year-on-year change?
What is Opiant Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of OPNT is $5.82 M
What is the all time high annual EBITDA for Opiant Pharmaceuticals?
Opiant Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is $11.65 M
What is Opiant Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, OPNT annual earnings before interest, taxes, depreciation & amortization has changed by +$7.37 M (+476.30%)
What is Opiant Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of OPNT is -$9.51 M
What is the all time high quarterly EBITDA for Opiant Pharmaceuticals?
Opiant Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $10.64 M
What is Opiant Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, OPNT quarterly earnings before interest, taxes, depreciation & amortization has changed by -$13.49 M (-338.81%)
What is Opiant Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of OPNT is -$30.70 M
What is the all time high TTM EBITDA for Opiant Pharmaceuticals?
Opiant Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is $11.87 M
What is Opiant Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, OPNT TTM earnings before interest, taxes, depreciation & amortization has changed by -$34.16 M (-987.52%)